Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.68 USD | +6.27% | +3.05% | +33.33% |
04-10 | Transcript : Chemomab Therapeutics Ltd. - Special Call | |
03-07 | Chemomab Therapeutics Ltd. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 | CI |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 9.09M 724M |
---|---|---|---|---|---|
Net income 2024 * | -15M -1.19B | Net income 2025 * | -22M -1.75B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-10.7
x | P/E ratio 2025 * |
-8.53
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 4.97% |
Latest transcript on Chemomab Therapeutics Ltd.
1 day | +6.27% | ||
1 week | +3.05% | ||
Current month | -12.71% | ||
1 month | -11.83% | ||
3 months | +25.93% | ||
6 months | -8.11% | ||
Current year | +33.33% |
Managers | Title | Age | Since |
---|---|---|---|
Adi Mor
CEO | Chief Executive Officer | 43 | 21/09/11 |
Sigal Fattal
DFI | Director of Finance/CFO | 53 | 31/12/19 |
Chief Tech/Sci/R&D Officer | 56 | 13/11/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Neil Cohen
BRD | Director/Board Member | 60 | 31/03/20 |
Nissim Darvish
CHM | Chairman | 59 | 15/03/21 |
Claude Nicaise
BRD | Director/Board Member | 71 | 15/03/21 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 0.68 | +6.27% | 19 959 |
26/04/24 | 0.6399 | -2.90% | 23,560 |
25/04/24 | 0.659 | -1.64% | 11,541 |
24/04/24 | 0.67 | 0.00% | 3,426 |
23/04/24 | 0.67 | +1.53% | 7,157 |
Delayed Quote Nasdaq, April 29, 2024 at 09:00 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+33.33% | 9.09M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- CMMB Stock